- « Previous
- Clinical Pharmacology
- Next »
Hyalgan
Clinical Pharmacology
Clinical Pharmacology
Hyalgan
| NUMBER (%) OF SUBJECTS IN CATEGORY | ||||||
| Hyalgan® | Placebo | Naproxen | ||||
| Baseline | Week 26 | Baseline | Week 26 | Baseline | Week 26 | |
None (0) |
1 (1.0) | 23 (21.9) | 0 (0.0) | 14 (12.2) | 0 (0.0) | 13 (11.5) |
Slight (1) |
2 (1.9) | 27 (25.7) | 0 (0.0) | 24 (20.9) | 1 (0.9) | 31 (27.4) |
Mild (2) |
6 (5.7) | 19 (18.1) | 8 (7.0) | 24 (20.9) | 7 (6.2) | 26 (23.0) |
Moderate (3) |
62 (59.0) | 26 (24.8) | 78 (67.8) | 40 (34.8) | 72 (63.7) | 31 (27.4) |
Marked (4) |
34 (32.4) | 10 (9.5) | 29 (25.2) | 13 (11.3) | 33 (29.2) | 12 (10.6) |
TOTAL |
105 (100) | 105 (100) | 115 (100) | 115 (100) | 113 (100) | 113 (100) |
Assessment |
Hyalgan® (HYL) |
Placebo (PLA) |
Naproxen (NAP) |
HYL-PLA | NAP-HYL | NAP-PLA | (HYL-PLA) % of (NAP-PLA) |
VAS for 50 foot Walk Baseline Adjusted Mean Effect Sizes From ANCOVA |
-8.85 mm on a 100 mm VAS |
4.12 mm on a 100 mm VAS |
-4.73 * mm on a 100 mm VAS |
187% |
|||
% of Subjects Improved by Masked Evaluators |
78.1 | 69.6 | 73.2 | 8.5 | -4.9 | 3.6 | 236% |
% of Subjects Improved by Subjects |
73.3 | 62.6 | 67.3 | 10.7 | -6.0 | 4.7 | 228% |
*Imputed as (NAP-HYL) + (HYL-PLA). Note that Effectiveness Success Criterion D is satisfied since ((HYL-PLA) % of (NAP-PLA))>50% for all three of the above pain assessments. |
|||||||
Additional Analyses
Brand Name: Hyalgan
Generic Name: Hyaluronate
Generic Name: Hyaluronate
- « Previous
- Clinical Pharmacology
- Next »
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Arthritis
Get the latest treatment options
WebMD Resources
Knee Cartilage Restoration
Advances in technology are helping painful old knees work like new again. See more WebMD Videos »
